pubmed-article:12467390 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0003232 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0205103 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0002505 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0002482 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0598405 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0075804 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0061633 | lld:lifeskim |
pubmed-article:12467390 | lifeskim:mentions | umls-concept:C0233656 | lld:lifeskim |
pubmed-article:12467390 | pubmed:issue | 25 | lld:pubmed |
pubmed-article:12467390 | pubmed:dateCreated | 2002-12-6 | lld:pubmed |
pubmed-article:12467390 | pubmed:abstractText | Nocathiacin I (1) and nocathiacin IV (2) are novel indole-containing thiazolyl peptide antibiotics, which exhibit potent activity against key Gram-positive bacterial pathogens, including multi drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecium. New nocathiacins 7-12 were prepared from 2 by a condensation with glycolaldehyde followed by tandem reductive amination of the 2-oxoethyl intermediate 4. The latter was formed via Amadori rearrangement from initial 2-hydroxyethylideneamide 3. This transformation readily tolerates the complex architecture of nocathiacins and allows selective incorporation of water solubilizing groups to the primary amide in 2 without protecting group manipulation. | lld:pubmed |
pubmed-article:12467390 | pubmed:language | eng | lld:pubmed |
pubmed-article:12467390 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12467390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12467390 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12467390 | pubmed:month | Dec | lld:pubmed |
pubmed-article:12467390 | pubmed:issn | 0022-3263 | lld:pubmed |
pubmed-article:12467390 | pubmed:author | pubmed-author:HuangStellaS | lld:pubmed |
pubmed-article:12467390 | pubmed:author | pubmed-author:LeetJohn EJE | lld:pubmed |
pubmed-article:12467390 | pubmed:author | pubmed-author:UedaYasutsugu... | lld:pubmed |
pubmed-article:12467390 | pubmed:author | pubmed-author:HrnciarPeterP | lld:pubmed |
pubmed-article:12467390 | pubmed:author | pubmed-author:BronsonJoanne... | lld:pubmed |
pubmed-article:12467390 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12467390 | pubmed:day | 13 | lld:pubmed |
pubmed-article:12467390 | pubmed:volume | 67 | lld:pubmed |
pubmed-article:12467390 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12467390 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12467390 | pubmed:pagination | 8789-93 | lld:pubmed |
pubmed-article:12467390 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:meshHeading | pubmed-meshheading:12467390... | lld:pubmed |
pubmed-article:12467390 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:12467390 | pubmed:articleTitle | Synthesis of novel nocathiacin-class antibiotics. Condensation of glycolaldehyde with primary amides and tandem reductive amination of amadori-rearranged 2-oxoethyl intermediates. | lld:pubmed |
pubmed-article:12467390 | pubmed:affiliation | Bristol-Myers Squibb Co., Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut 06492, USA. | lld:pubmed |
pubmed-article:12467390 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12467390 | lld:pubmed |